Cover; Contents; Introduction and Epidemiology; Pathophysiology; Regulatory Factors in Thrombus Formation; Cellular Interactions in Atherothrombosis; Classification of Stroke; Managing Risk Factors for Recurrent Stroke; Antithrombotic Therapy for Prevention of Recurrent TIA and Stroke; Aspirin; Mechanism of Action; Pharmacokinetics; Adverse Effects; Aspirin Administration in Clinical Practice; Secondary Prevention of Vascular Events and Stroke; Aspirin Dosing in Prevention of Recurrent TIA/Stroke; Thienopyridines (Clopidogrel, Ticlopidine, and Prasugrel); Mechanism of Action; Clopidogrel
PharmacokineticsAbsorption; Adverse Effects; Prevention of Vascular Events; Ticlopidine; Prasugrel; Dipyridamole, Extended-Release Dipyridamole/Aspirin Combination (Aggrenox); Mechanism of Action; Pharmacokinetics; Pharmacodynamics; Adverse Effects; Administration in Older Patients; Clinical Experience; Cilostazol; References
Summary
Stroke is the most common cause of adult mortality in the United States. Antithrombotic agents form the mainstay of stroke prevention. Aspirin produces a modest reduction in the risk of second stroke and transient ischemic attack (TIA, mini-stroke) and is widely recommended for initial therapy. The thienopyridines (Ticlid) and clopodogrel (Plavix) are alternatives for secondary prevention in patients who do not respond to or cannot take aspirin. They are no more effective than aspirin and have been associated with thrombotic thrombocytopenic purpura. The combination of aspirin and extended-rel.
